首页> 美国卫生研究院文献>Carcinogenesis >FXR-Gankyrin axis is involved in development of pediatric liver cancer
【2h】

FXR-Gankyrin axis is involved in development of pediatric liver cancer

机译:FXR-Gankyrin轴参与小儿肝癌的发展

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The development of hepatoblastoma (HBL) is associated with failure of hepatic stem cells (HSC) to differentiate into hepatocytes. Despite intensive investigations, mechanisms of the failure of HSC to differentiate are not known. We found that oncogene Gankyrin (Gank) is involved in the inhibition of differentiation of HSC via triggering degradation of tumor suppressor proteins (TSPs) Rb, p53, C/EBPα and HNF4α. Our data show that the activation of a repressor of Gank, farnesoid X receptor, FXR, after initiation of liver cancer by Diethylnitrosamine (DEN) prevents the development of liver cancer by inhibiting Gank and rescuing tumor suppressor proteins. We next analyzed FXR-Gank-Tumor suppressor pathways in a large cohort of HBL patients which include 6 controls and 53 HBL samples. Systemic analysis of these samples and RNA-Seq approach revealed that the FXR-Gank axis is activated; markers of hepatic stem cells are dramatically elevated and hepatocyte markers are reduced in HBL samples. In the course of these studies, we found that RNA binding protein CUGBP1 is a new tumor suppressor protein which is reduced in all HBL samples. Therefore, we generated CUGBP1 KO mice and examined HBL signatures in the liver of these mice. Micro-array studies revealed that the HBL-specific molecular signature is developed in livers of CUGBP1 KO mice at very early ages. Thus, we conclude that FXR-Gank-TSPs-Stem cells pathway is a key determinant of liver cancer in animal models and in pediatric liver cancer. Our data provide a strong basis for development of FXR-Gank-based therapy for treatment of patients with hepatoblastoma.
机译:肝母细胞瘤(HBL)的发展与肝干细胞(HSC)不能分化为肝细胞有关。尽管进行了深入的研究,HSC未能分化的机制尚不清楚。我们发现致癌基因Gankyrin(Gank)通过触发肿瘤抑制蛋白(TSP)Rb,p53,C /EBPα和HNF4α的降解来抑制HSC的分化。我们的数据表明,由二乙基亚硝胺(DEN)引发肝癌后,Gank阻遏物,法呢素X受体FXR的激活通过抑制Gank和抢救肿瘤抑制蛋白来预防肝癌的发展。接下来,我们分析了一大批HBL患者的FXR-Gank-肿瘤抑制因子通路,其中包括6个对照和53个HBL样本。对这些样品和RNA-Seq方法的系统分析表明,FXR-Gank轴已激活。 HBL样品中肝干细胞的标志物显着升高,而肝细胞标志物则降低。在这些研究过程中,我们发现RNA结合蛋白CUGBP1是一种新型的肿瘤抑制蛋白,在所有HBL样品中均降低。因此,我们生成了CUGBP1 KO小鼠,并检查了这些小鼠肝脏中的HBL信号。微阵列研究表明,在很早的年龄就在CUGBP1 KO小鼠的肝脏中形成了HBL特异性分子标记。因此,我们得出结论,FXR-Gank-TSPs-干细胞途径是动物模型和小儿肝癌中肝癌的关键决定因素。我们的数据为开发基于FXR-Gank的肝母细胞瘤患者疗法提供了坚实的基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号